)
Visual
earnings real time
Microba Life Sciences
Microba Life Sciences (MAP) investor relations material
Microba Life Sciences Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary29 Jan, 2026
Executive summary
Core clinical testing volumes grew 90% year-on-year, with an annualized run rate exceeding 21,300 tests and on track to surpass 24,000 for regional break-even in Australia and the UK by FY26.
Microbiome Explorer now represents 55% of total revenue, reflecting a full transition from legacy products, which are now fully discontinued.
UK market adoption is 33% higher than Australia at the equivalent post-launch period, leveraging an acquired customer base and enhanced product features.
AI-driven transformation has delivered significant operational efficiencies, with over 70% of customer inquiries resolved autonomously and a 94.7% satisfaction score.
Major brand consolidation and new product features, such as the Oral Species Biomarker and Pay on Invoice, have improved operational efficiency and clinical utility.
Financial highlights
Core testing revenue rose 123% year-on-year, with Q2 FY26 total revenue at $3.72m and FY25 revenue at $15.67m.
Over $1.6 million in legacy product revenue replaced by core products, with legacy product roll-off now complete.
UK Invivo-branded supplements delivered a record quarter, with PHGG prebiotic supplement volumes up 110% year-on-year.
Net operating cash outflows reduced to $1.6m in Q2 FY26, reflecting cost reductions and R&D tax incentive receipt.
Cash balance as of 31 Dec 2025 was $11.27 million, with estimated 7 quarters of funding at current burn rate.
Outlook and guidance
On track for regional break-even in Australia and the UK by FY26, targeting over 24,000 core tests for the full year.
Group EBITDA break-even expected with further scale and continued strong clinical adoption.
Expansion into the US and Europe planned, contingent on regulatory pathways and successful laboratory partnerships.
Expect continued acceleration in clinical adoption and revenue growth as legacy product wind-down is complete.
Cash receipts expected to normalize from Q3 FY26 as payment term changes cycle through.
What specific results will unlock therapeutic deals?
How does product-led growth reduce customer acquisition cost?
Detail non-dilutive funding opportunities
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- ATS
Q3 revenue up 16.7% and net income surges, with Q4 revenue guided at $710–$750 million. - SWK
Gross margin and net income rose, with CAM divestiture set to reduce debt and boost 2026 outlook. - PMI
FDA-approved artificial heart maker registers 17M shares for resale amid ongoing losses and risks. - ARCC
FY 2025 net income was $1,299M, with a $0.48/share Q1 2026 dividend declared. - BG
2025 delivered solid EBIT and cash flow, with 2026 guidance indicating stable adjusted EPS. - SDST
Development-stage lithium refiner registers shares for resale amid high risk and capital needs. - DAC
Q2 2025 saw revenue growth, high charter coverage, and strong liquidity despite rising costs. - OCSL
Net investment income was $36.7M ($0.42/share) as NAV fell to $16.30 and a $0.40 dividend was declared. - NUWE
Registering 4.28M shares for resale, proceeds from warrant exercises support working capital. - WBD
Board selects Netflix merger for streaming and studios, with Discovery Global to be spun off.
Microba Life Sciences
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Microba Life Sciences Limited is a biotechnology company specializing in microbiome analysis and therapeutics. The company provides advanced gut microbiome testing services using metagenomic sequencing technology to offer insights into human health. Microba also conducts research and development to discover and develop microbiome-based therapeutics targeting conditions such as inflammatory and metabolic diseases. The company is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage